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Sir, Autosomal dominant optic atrophy (DOA) is the most com-
monly diagnosed inherited optic neuropathy in clinical practice and
the majority of patients harbour pathogenic mutations within
the OPA1 gene (3q28-q29, OMIM 165500) (Yu-Wai-Man and
Chinnery, 2013). OPA1 is a multifunctional protein located
within the mitochondrial inner membrane and it regulates a
number of critical cellular functions, including mitochondrial net-
work stability, oxidative phosphorylation and mitochondrial cell
death pathways (Lenaers et al., 2009). Until recently, DOA was
largely viewed as a limited genetic disorder that preferentially af-
fects retinal ganglion cells resulting in progressive visual failure
from early childhood (Carelli et al., 2004; Yu-Wai-Man et al.,
2014). It is now abundantly clear that pathogenic OPA1 mutations
can have much more severe multisystemic consequences that are
detrimental not only to optic nerve function, but also target other
tissues that are frequently involved in other well-established mito-
chondrial syndromes (Amati-Bonneau et al., 2008; Hudson et al.,
2008). In a large multicentre study published in Brain, up to 20%
of OPA1 mutation carriers developed these so-called DOA plus
(DOA+ ) phenotypes where the optic atrophy was complicated
by a wide range of neuromuscular features that included ataxia,
myopathy, peripheral neuropathy, sensorineural deafness, and fas-
cinatingly, chronic progressive external ophthalmoplegia (Yu-
Wai-Man et al., 2010).
A previous case report in Brain described two brothers diag-
nosed with classical Behr’s syndrome who were eventually found
to carry a single heterozygous pathogenic OPA1 mutation
(c.1652G4A, p.Cys551Tyr) within the catalytic GTPase domain
(Marelli et al., 2011; Yu-Wai-Man and Chinnery, 2011). In their
case series, Bonneau and colleagues extend the association
between pathogenic OPA1 mutations and Behr’s syndrome with
a detailed account of four unrelated children who developed the
typical clinical features of an early-onset progressive optic neuro-
pathy that was further compounded by ataxia, spasticity and per-
ipheral neuropathy (Bonneau et al., 2014). Their most striking
observation is the identification of compound heterozygous
OPA1 mutations in all four patients with the co-occurrence of a
missense GTPase mutation and a truncative nonsense mutation.
Interestingly, three of these families harboured the same missense
GTPase OPA1 mutation (c.1146A4G, p.Ile382Met) that has been
previously reported in another DOA+ family with compound het-
erozygous mutations (Schaaf et al., 2011). This specific pathogenic
variant is clearly highly penetrant for the neurological ‘plus’ fea-
tures and it does support our earlier observation that misssense
GTPase OPA1 mutations seem to have a more potent deleterious
impact, possibly via a dominant negative mechanism and
increased mitochondrial DNA instability (Yu-Wai-Man et al.,
2010; Yu-Wai-Man and Chinnery, 2012). As Bonneau et al.
(2014) correctly point out, we did describe two siblings from a
non-consanguineous Norwegian family in our original Brain paper,
who developed a particularly aggressive disease course character-
ized by ataxia, spasticity, peripheral neuropathy and myopathy
(Yu-Wai-Man et al., 2010). OPA1 sequencing identified two
pathogenic variants in both the affected brother and sister: the
c.768C4G (p.Ser256Arg) missense mutation in exon 5b and the
c.854A4G (p.Gln285Arg) missense mutation in exon 8. Bonneau
et al. (2014) rightly queried whether we had actually proven com-
pound heterozygosity in these two affected Norwegian siblings.
Although DNA was not available from their deceased parents,
we did have access to DNA samples from the brother’s two
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unaffected daughters and both harboured only the c.768C4G
(p.Ser256Arg) substitution in exon 5b. Furthermore, haplotype
analysis provided additional evidence that the proband and his
affected sister were indeed compound heterozygous for the
c.768C4G (p.Ser256Arg) and the c.854A4G (p.Gln285Arg)
OPA1 mutations (Yu-Wai-Man et al., 2010).
Three Opa1 mouse models have been developed harbouring
truncative mutations in exon 8 (c.1051C4T) (Davies et al.,
2007), intron 10 (c.1065+5G4A) (Alavi et al., 2007), and exon
27 (c.2708–2711delTTAG) (Sarzi et al., 2012). Heterozygous
mutant mice exhibited 50% reduction in overall protein expres-
sion, in keeping with a haploinsufficiency mechanism, and these
mice faithfully replicated the human phenotype with a slowly pro-
gressive bilateral optic neuropathy and reduced visual parameters.
Optic nerve degeneration was documented as early as 6 months,
but it was much more striking by 2 years of age. Interestingly, in
all three Opa1 mouse models, homozygous mutant mice died in
utero during early embryogenesis, clearly highlighting the central
role played by OPA1 in early development. This major profusion
protein has been highly conserved throughout evolution and it is
perhaps not surprising that so far, no affected individuals have
been reported that carry homozygous or compound heterozygous
nonsense or frameshift OPA1 mutations, which are likely to be
embryonically lethal.
The final clinically relevant point that we would like to make
relates to the use of Behr’s syndrome (OMIM 210000) as a diag-
nostic label. In 1909, Carl Behr, a German ophthalmologist,
described an infantile form of optic atrophy complicated by
mental retardation and spinocerebellar degeneration that resulted
in ataxia, spasticity and peripheral neuropathy (Behr, 1909). The
genetic advances of the past two decades have transformed our
understanding of human diseases and with the greater availability
of next-generation sequencing technology, it has become appar-
ent that most eponymous syndromes have a heterogeneous mo-
lecular genetic basis and should be viewed as largely historical
descriptions. Behr’s syndrome is a very good illustration of this
fundamental shift in genetic disease classification, based not
solely on the clustering of recognizable clinical features, but pri-
marily on the identification of the underlying genetic defects. This
syndromic inherited optic neuropathy was originally linked to
autosomal recessive OPA3 mutations among Iraqi Jewish patients
with elevated urinary excretion of 3-methylglutaconic acid and
3-methylglutaric acid—a subtype that was known by yet another
eponymous description, namely Costeff syndrome (Costeff et al.,
1989; Anikster et al., 2001). Besides OPA3, we now know that
both single and compound heterozygous OPA1 mutations can
result in multisystemic DOA+ phenotypes that would be entirely
consistent with Carl Behr’s original case report. This is certainly not
the end of the story and the list of disease-causing genes is bound
to grow even further, a fact that is clearly exemplified by the
recent identification of compound homozygous C12orf65 muta-
tions in patients with phenotypic manifestations indistinguishable
to those classically associated with ‘Behr’s syndrome’ (Pyle et al.,
2014). Downregulation of the C12orf65 protein results in a mito-
chondrial translation defect and profound multiple respiratory
chain defects. Despite the underlying genetic heterogeneity, a
unifying theme is clearly emerging in ‘Behr’s syndrome’ with
mitochondrial dysfunction being the final common pathway that
is ultimately leading not only to retinal ganglion cell loss and optic
nerve degeneration, but also to more widespread neuronal loss
with multisystemic manifestation. Generic treatment modalities
aimed at correcting these dysfunctional mitochondrial mechanisms
could therefore prove beneficial to this group of patients irrespect-
ive of the causative genetic defect.
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